Compare PepsiCo, Inc. (PEP) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
PepsiCo, Inc. vs Sanofi SA — how do they compare? PepsiCo, Inc. trades at $135.1 (market cap $184.26B), while Sanofi SA trades at $44.02 (market cap $104.85B). The key difference: PepsiCo, Inc. is the larger of the two by market cap, and Sanofi SA pays the higher dividend (5.53%). Which is the better fit depends on your goals.
| PEP | SNY | |
|---|---|---|
Market Cap | $184.26B | $104.85B |
Sector | Consumer Staples | Health |
52-Week High | $170.44 | $52.34 |
52-Week Low | $134.98 | $41.33 |
Enterprise Value | $226.76B | $121.38B |
Dividend Yield | 4.39% | 5.53% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PepsiCo (PEP) trades at $135.1, down 0.27% on the day, with a bearish technical signal from moving averages. The company reported revenue of $93.93B in 2025 with a net income margin of 10.78%, though earnings declined year-over-year. Recent news highlights price cuts on snacks like Doritos to address consumer pushback, while analysts expect in-line Q1 2026 results. Dividends of $1.48 per share were paid in H1 and H2 2026, supporting income investors.
PEP's outlook is mixed: analyst consensus targets $158.79 (17.5% upside) with a 'Hold' bias, but technicals and recent net income dip pose near-term risks. Opportunities include margin recovery from cost controls and steady cash flow, while risks involve competitive pressures and consumer sensitivity to pricing. The stock's valuation at a P/E of 17.69 appears reasonable if earnings rebound as projected for 2026.
SNY trades at $43.76, down 2.02% today, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 results pending. Revenue grew to $46.72B in 2025, with net income margin improving to 16.72%. Recent positive developments include FDA approval for Sarclisa's wearable injector and EU approval for Cenrifki in multiple sclerosis.
Outlook remains positive with analyst consensus leaning toward buy/hold, though regulatory scrutiny in the EU presents near-term risk. The stock offers a solid dividend yield with the upcoming $2.42 payment. Valuation metrics like P/E of 19.5 and P/B of 1.27 suggest reasonable pricing relative to peers, supported by robust cash flow from operations of $10.75B.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About PepsiCo, Inc.
PepsiCo is one of the largest food and beverage companies globally. It makes, markets, and sells a slew of brands across the beverage and snack categories, including Pepsi, Mountain Dew, Gatorade, Doritos, Lays, and Ruffles. The firm uses a largely integrated go-to-market model, though it does leverage third-party bottlers, contract manufacturers, and distributors in certain markets. In addition to company-owned trademarks, Pepsi manufactures and distributes other brands through partnerships and joint ventures with companies such as Starbucks. The firm segments its operations into five primary geographies, with North America (comprising Frito-Lay North America, Quaker Foods North America, and North America beverages) constituting around 60% of consolidated revenue.
Read more on PEP →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
